MedTrace Logo

Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation

NCT03746782 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-01-23

No results posted yet for this study

Summary

Investigating Synergistic Effects of Apixaban with Dual Anti-Platelet Therapy (DAPT) in Lowering Platelet Reactivity and Thrombin Generation

Conditions

  • Acute Coronary Syndrome

Interventions

DIAGNOSTIC_TEST

Flow Cytrometry; Thrombin Generation Assay

Apixaban combined with blood specimens (in vitro) of study participants

Sponsors & Collaborators

  • CirQuest Labs, LLC

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-10
Primary Completion
2019-11-08
Completion
2019-11-08

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03746782 on ClinicalTrials.gov